1. Home
  2. BNED vs ZURA Comparison

BNED vs ZURA Comparison

Compare BNED & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barnes & Noble Education Inc

BNED

Barnes & Noble Education Inc

N/A

Current Price

$12.46

Market Cap

440.9M

ML Signal

N/A

Logo Zura Bio Limited

ZURA

Zura Bio Limited

N/A

Current Price

$0.96

Market Cap

455.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNED
ZURA
Founded
1965
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.9M
455.4M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
BNED
ZURA
Price
$12.46
$0.96
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
★ $17.25
$8.00
AVG Volume (30 Days)
147.9K
★ 6.7M
Earning Date
12-08-2026
10-27-2026
Dividend Yield
★ 2.49%
N/A
EPS Growth
★ 119.60
N/A
EPS
★ N/A
N/A
Revenue
★ $1,714,770,000.00
N/A
Revenue This Year
$2.88
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 6.50
N/A
52 Week Low
$5.90
$0.93
52 Week High
$14.75
$7.25

Technical Indicators

Market Signals
Indicator
BNED
ZURA
Relative Strength Index (RSI) 46.99 24.55
Support Level $11.55 N/A
Resistance Level $13.11 $5.97
Average True Range (ATR) 0.48 0.24
MACD -0.09 -0.18
Stochastic Oscillator 21.10 0.02

Price Performance

Historical Comparison
BNED
ZURA

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is contract operators of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also one of the textbook wholesalers and inventory management hardware and software providers The company operates physical and virtual bookstores that delivers essential educational content and general merchandise within a dynamic omnichannel retail environment. The Company currently operates as a single operating and reporting segment. The company's solutions are Academic Solutions, College Retail Solutions, College Insights, Wholesale & Store Technology Services.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Share on Social Networks: